Stakk Secures FBI Deployment for Signature Verification Technology
Get your Free Report on Top 5 ASX stocks for 2025
Digital trust infrastructure provider Stakk Limited (ASX: SKK) announced on Tuesday, 29 September 2026 that its wholly owned subsidiary ParaScript has been engaged to deliver signature verification capabilities for the United States Federal Bureau of Investigation (FBI).
Working alongside a U.S. government strategic partner, the company's technology facilitates the assessment of physical signatures to detect potential fraud and verify authenticity. The initial deployment phase is fully live with development underway on a second phase designed to locate and prepare reference signatures for the verification workflow.
While specific commercial terms and operational details remain confidential, the underlying agreement runs through December 2027 and includes 12-month auto renewal terms. The company noted the engagement will contribute meaningfully to its FY2027 revenue target which is now expected to surpass $55 million.
Stakk highlighted that the contract establishes a critical operational footprint within law enforcement, validating its solutions in sectors where document authenticity is vital. Management anticipates accelerating demand for signature verification across enterprise sectors amid rising AI-driven fraud including financial services, healthcare and telecommunications while positioning the company to pursue further contracts with U.S. state, federal and international agencies.
(Source: Company Announcements)
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether itβs appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
Feature News
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialRecent News
Rubicon Water Secures $12M Irrigation Modernisatio..
Memphasys Targets Fast-Track FDA Pathway for Felix..
Mesoblast Secures FDA Clearance for New Ryoncil Co..
BCAL Diagnostics (ASX:BDX) Launches Avantect Multi..
Genetic Signatures and Microba Agree to Commercial..